Clinical trial NCT03979885: Financial Incentives for Smoking Treatment II
Official title: Financial Incentives for Smoking Treatment
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: NA
Conditions: Smoking Cessation
Tobacco Use Cessation
Lead sponsor: University of California, Los Angeles
Sponsor class: OTHER
Collaborators: name: NYU Langone Health
name: Olive View-UCLA Education & Research Institute
First posted: 2019-06-07
Enrollment: 1058
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Financial incentives for motivating changes in health behavior, particularly for smoking and other morbid habits, are increasingly being tested by health insurers, employers, and government agencies. However, in using incentive programs for smoking cessation, key unanswered structural and theoretical questions remain regarding their effectiveness, acceptability to patients, and economic sustainability. This trial aims to advance the science and implementation of financial incentives for smoking cessation interventions among high-risk, hospitalized smokers. The investigators will pursue two specific aims: 1) comparing the impact of three approaches for smoking cessation on smoking abstinence, use of evidenced-based therapy, and quality of life and 2) comparing the short-term and long term return on investment of using goal directed and outcome-based financial incentives to promote smoking cessation.


Eligibility criteria: Inclusion Criteria:

1. age ≥ 18 years
2. smoked tobacco during the prior 30 days,
3. have an active U.S. phone number and address,
4. can provide consent in English or Spanish and
5. are in at least the contemplative stage of change for quitting smoking, as assessed by a single measure, readiness to quit

Exclusion Criteria:

1. use only smokeless tobacco,
2. are pregnant or breastfeeding,
3. are discharged to an institution (e.g., nursing home, long-term care facility),
4. are unable to provide informed consent, or do not have cognitive ability to enroll or participate in the study

Primary outcomes:
measure: Smoking abstinence assessed by self-report and biochemically verified by salivary cotinine
timeFrame: 6 months
Secondary outcomes:
measure: Use of evidence based treatment (e.g. counseling and smoking cessation medications) assessed by discharge prescriptions, Quitline records, receipts, letters and/or self-report
timeFrame: 2 months
measure: Quality of life as measured by PROMIS-29 Profile v2.0
timeFrame: 12 months
measure: Short term return on investment of using financial incentives to promote smoking cessation (Cost analysis)
timeFrame: 12 months
measure: Long term return on investment of using financial incentives to promote smoking cessation (Cost analysis)
timeFrame: 3 years
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: David Geffen School of Medicine
state: California
city: New York
country: United States
facility: NYU Langone Health
state: New York
Study officials:
affiliation: University of California, Los Angeles
name: Joseph Ladapo, MD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: NYU Langone Health
name: Scott Sherman, MD
role: PRINCIPAL_INVESTIGATOR
References: